الرئيسية » أرشيف الكاتب: Catherine Skari

أرشيف الكاتب: Catherine Skari

FDA Accelerates Review Of Sickle Cell Disease Medicine Crizanlizumab

Novartis announced earlier today the FDA accepted the company’s Biologics License Application (BLA) and has granted Priority Review for its investigational Sickle Cell (SCD) medicine Crizanlizumab. If FDA-approved, crizanlizumab is expected to represent the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease! Novartis submitted the application ...

أكمل القراءة »

Drones Land in the Cell and Gene Therapy Space

Cell and gene therapies could be literally flying high soon from now! The Italy-based biotech company Anemocyte, in collaboration with RPS Aerospace,  developed a remotely piloted drone system to securely transport final cell and gene therapy products straight from manufacturing sites to clinical centers. The current prototype can also transport ...

أكمل القراءة »

Bluebird puts €1.58m price on gene therapy Zynteglo

  Bluebird bio Inc. set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe earlier this month to to treat patients 12 years and older with transfusion-dependent β-thalassaemia (TDT), who have no matching donor for a stem ...

أكمل القراءة »

FROM PUMP TO PILL by Chanapa Tantibanchachai

Winner Story #1 – International Thalassaemia Day 2018   ”As I reflect on my past, present and future as a thalassemia patient, I can’t help but be in complete awe of the clinical advances that have been made just in the past two and a half decades that I’ve been ...

أكمل القراءة »

مييا حمااكة واقعي مع الثالس by Hanady Alsanwi

Winner Story #2– International Thalassaemia Day 2018   متكرر ما بني الفرتة واألخرى ونظرات ً ال يفارق جسدي ونقل دما ً للمستشفى وآملا يف اعني و الدي ً خوفا و صعوبة احلياة اجلسدية واحلياة الواقعية يف ظل احلروب الدائمة يف بالدنا وصعوبة العيش وانقطاع االدوية بشكل مستمر , اصبح اآلمل ...

أكمل القراءة »

A milestone in the treatment of b-thalassaemia – The 1st gene therapy for Transfusion Dependent β-Thalassaemia wins approval in Europe

  Zynteglo, Bluebird Bio’s ex vivo gene therapy for β-thalassaemia, got a green light from the EMA for conditional marketing authorization making it the 1st gene therapy for patients with thalassaemia to win such an approval.  The one-time gene therapy has been approved for patients 12 years and older with ...

أكمل القراءة »